News|Articles|April 3, 2026

ELCC 2026: Key Updates Across Non–Small Cell Lung Cancer Populations

Fact checked by: Ariana Pelosci, Tracy Ann Politowicz

Poster presentations at ELCC 2026 highlighted potential advances in neoadjuvant immunotherapy, intratumoral radioenhancers, and other modalities.

At the 2026 European Lung Cancer Congress (ELCC), lung cancer experts around the world convened in Copenhagen, Denmark, to exchange findings and insights on potential advances in the research and care of different patient populations. As part of various poster sessions focusing on non–small cell lung cancer (NSCLC), specifically, experts presented trial updates on investigational immunotherapies, chemoradiation regimens, and other modalities that may impact the treatment paradigm.